Early Onset Preeclampsia and Nectin-4
Serum Nectin-4 Levels in Patients With Early Onset Preeclampsia
1 other identifier
observational
84
1 country
1
Brief Summary
Early-onset Preeclampsia (PE) is a pregnancy disorder which may present with adverse pregnancy outcomes. Nectin-4 is an adhesion molecule mainly expressed in placenta. This study aimed to evaluate the relationship between early onset Preeclampsia and serum Nectin 4 levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2020
CompletedFirst Submitted
Initial submission to the registry
October 16, 2021
CompletedFirst Posted
Study publicly available on registry
October 28, 2021
CompletedOctober 28, 2021
October 1, 2021
8 months
October 16, 2021
October 16, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
serum nectin-4 levels
ng/ml
1 hour
Secondary Outcomes (2)
BMI (body mass index)
5 minute
Tansion Arterial
5 minute
Study Arms (2)
Group 1 (Early onset Preeclampsia )
43 cases The groups were matched for gestational age and gravidity.
Group 2 ( Healthy pregnant woman) control group
41 cases The groups were matched for gestational age and gravidity
Interventions
two groups comparisons
Eligibility Criteria
Comparison to the level of soluble nectin-4 in early-onset PE, compared to healthy pregnancies
You may qualify if:
- spontaneous,
- singleton pregnancies
- above the 24 weeks of gestations
- positive fetal cardiac activity
You may not qualify if:
- multiple gestations,
- chronic hypertension
- hypothyroidism
- known malignancy,- diabetes mellitus,
- presence of fetal or maternal infection,
- clinical signs of chorioamnionitis (maternal fever, vaginal discharge, fetal tachycardia),
- hepatic or renal failure
- Placenta previa or pregnancies accompanied congenital fetal abnormalities or aneuploidies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hatice Akkayalead
Study Sites (1)
Hatice Akkaya
Istanbul, 34010, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- associate professor
Study Record Dates
First Submitted
October 16, 2021
First Posted
October 28, 2021
Study Start
May 1, 2020
Primary Completion
December 15, 2020
Study Completion
December 30, 2020
Last Updated
October 28, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- 1 year
- Access Criteria
- journals editors request
If needed